After Appeals Court Victory, Myriad Looks to Debunk 'Misconceptions' on How it Enforces DNA Patents | GenomeWeb

Originally published Aug. 21.

Pleased with the federal appeals court's recent decision to uphold gene patents related to its BRACAnalysis test, Myriad Genetics took the opportunity last week to correct a few "common misconceptions" about the impact such patents might have on patients' access to genetic testing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.